Clinical trial
A Study of LY3435151 in Participants With Solid Tumors
NCT04099277
Study timeline
Study start (actual)2019-10-28Date precision: day
Registry last updated2021-08-31
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Solid Tumorunresolved
Triple-negative Breast Cancerunresolved
Gastric Adenocarcinomaunresolved
Head and Neck Squamous Cell Carcinomaunresolved
Cervical Carcinomaunresolved
High Grade Serous Ovarian Carcinomaunresolved
Hepatocellular Carcinomaunresolved
Undifferentiated Pleomorphic Sarcomaunresolved
Leiomyosarcomaunresolved
Interventions
LY3435151DRUG
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04099277 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.